These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 35230200)

  • 21. Rationalizing therapeutic approaches in Alzheimer's disease.
    Grossberg GT
    CNS Spectr; 2005 Nov; 10(11 Suppl 18):17-21. PubMed ID: 16273026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Capabilities of combined therapy of Alzheimer's disease].
    Vasenina EE; Veryugina NI; Levin OS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(11. Vyp. 2):45-50. PubMed ID: 36412156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors.
    Grossberg GT; Alva G; Hendrix S; Ellison N; Kane MC; Edwards J
    Alzheimer Dis Assoc Disord; 2018; 32(3):173-178. PubMed ID: 29771687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aducanumab for Alzheimer's disease: A regulatory perspective.
    Nisticò R; Borg JJ
    Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapy of Alzheimer's disease: current status and future development].
    Schmidt R; Neff F; Lampl C; Benke T; Anditsch M; Bancher C; Dal-Bianco P; Reisecker F; Marksteiner J; Rainer M; Kapeller P; Dodel R
    Neuropsychiatr; 2008; 22(3):153-71. PubMed ID: 18826870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease.
    Gauthier S; Molinuevo JL
    Alzheimers Dement; 2013 May; 9(3):326-31. PubMed ID: 23110864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic strategies for Alzheimer's disease in clinical trials.
    Godyń J; Jończyk J; Panek D; Malawska B
    Pharmacol Rep; 2016 Feb; 68(1):127-38. PubMed ID: 26721364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current treatment for Alzheimer disease and future prospects.
    Tariot PN; Federoff HJ
    Alzheimer Dis Assoc Disord; 2003; 17 Suppl 4():S105-13. PubMed ID: 14512816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease.
    Mukhopadhyay S; Banerjee D
    J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toward an early diagnosis and treatment of Alzheimer's disease.
    Nordberg A
    Int Psychogeriatr; 2003 Sep; 15(3):223-37. PubMed ID: 14756159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of memantine for the treatment of dementia.
    Lo D; Grossberg GT
    Expert Rev Neurother; 2011 Oct; 11(10):1359-70. PubMed ID: 21955192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Drug treatment of Alzheimer's dementia : Status quo and perspectives].
    Müller P; Fendt M; Müller NG
    Internist (Berl); 2019 Jul; 60(7):761-768. PubMed ID: 31139854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France.
    Touchon J; Lachaine J; Beauchemin C; Granghaud A; Rive B; Bineau S
    Eur J Health Econ; 2014 Nov; 15(8):791-800. PubMed ID: 23928827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefits and risks of add-on therapies for Alzheimer's disease.
    Magierski R; Sobow T
    Neurodegener Dis Manag; 2015 Oct; 5(5):445-62. PubMed ID: 26517312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease.
    Zhu CW; Livote EE; Scarmeas N; Albert M; Brandt J; Blacker D; Sano M; Stern Y
    Alzheimers Dement; 2013 Nov; 9(6):733-40. PubMed ID: 23332671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.